BVF Partners LP recently announced the acquisition of new stake in Selecta Biosciences Inc. (NASDAQ:SELB). The institutional investor has increased its shareholding in the Healthcare company by 129.80% to 8.29 million shares with purchase of 4.69 million shares. This fresh investment now brings its stake to 9.48% valued currently at $19.74 million. In addition, Mangrove Partners raised its holdings by 1.0 million to 6.55 million shares. And The Vanguard Group, Inc. has lifted its position by 125.11% or 2.0 million shares – to 3.6 million shares.
With over 1.12 million Selecta Biosciences Inc. (SELB) shares trading Monday and a closing price of $2.60 on the day, the dollar volume was approximately $2.91 million. The shares have shown a positive weekly performance of 11.59% and its price on 08/31/20 lost nearly -0.76%. Currently, there are 96.79M common shares owned by the public and among those 87.31M shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 7 analysts who have offered their price forecasts for SELB have a consensus price objective of $8.17. The analysts have set the share’s price value over the next 12 months at a high of $13.00 and a low of $4.00 should the stock experience a downside. Incidentally, analysts’ outlook for the Selecta Biosciences Inc. stock is 1.70 for the next 12 months. But an upside of 80.0% will see the stock hit the forecast high price target while mean target price for the stock is $8.50.
Insiders at the company have transacted a total of 14 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 10 of these insider trades were purchases, accounting for 1,516,392 shares. Insider sales of the common stock occurred on 4 occasions, with total insider shares sold totaling 1,257,927 shares.
The top 3 mutual fund holders in Selecta Biosciences Inc. are Fidelity Select Port. – Biotechno, Vanguard Total Stock Market Index, and Wasatch Ultra Growth Fund. Fidelity Select Port. – Biotechno owns 2.52 million shares of the company’s stock, all valued at over $5.99 million. The company bought an additional 2.52 million shares recently to bring their total holdings to about 2.88% of the shares outstanding. Vanguard Total Stock Market Index sold 8086.0 shares to see its total holdings shrink to 2.29 million shares valued at over $5.44 million and representing 2.61% of the shares outstanding. Wasatch Ultra Growth Fund now owns shares totaling to 1.61% of the shares outstanding.
Shares of Selecta Biosciences Inc. (NASDAQ: SELB) opened at $2.60, down -$0.02 from a prior closing price of $2.62. However, the script later closed the day at $2.60, down -0.76%. The company’s stock has a 5-day price change of 11.59% and -31.94% over the past three months. SELB shares are trading 9.24% year to date (YTD), with the 12-month market performance up to 46.07% higher. It has a 12-month low price of $1.28 and touched a high of $4.83 over the same period. Currently, 1.12 million shares have been traded, compared to an average intraday trading volume of 2.43 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 0.40%, -2.27%, and -6.33% respectively.
Institutional ownership of Selecta Biosciences Inc. (NASDAQ: SELB) shares accounts for 62.80% of the company’s 96.79M shares outstanding. Mutual fund holders own 27.00%, while other institutional holders and individual stakeholders account for 48.76% and 17.38% respectively.
It has a market capitalization of $272.19M and a beta (3y monthly) value of 1.28. The earnings-per-share (ttm) stands at -$1.00. Price movements for the stock have been influenced by the stock’s volatility, which stands at 7.72% over the week and 7.08% over the month.
Analysts forecast that Selecta Biosciences Inc. (SELB) will achieve an EPS of $0.1 for the current quarter, -$0.11 for the next quarter and -$0.23 for 2021. The lowest estimate earnings-per-share for the quarter is -$0.15 while analysts give the company a high EPS estimate of $0.65. Comparatively, EPS for the current quarter was -$0.26 a year ago. Earnings per share for the fiscal year are expected to increase by 58.40%, and 45.20% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 7 brokerage firm advisors rate Selecta Biosciences Inc. (SELB) as a “Strong Buy” at a consensus score of 1.70. Specifically, 6 Wall Street analysts polled rate the stock as a buy, while 1 of the 7 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the SELB, a number of firms have released research notes about the stock. Stifel stated their Hold rating for the stock in a research note on June 12, 2020, with the firm’s price target at. H.C. Wainwright coverage for the Selecta Biosciences Inc. (SELB) stock in a research note released on April 28, 2020 offered a Buy rating with a price target of $8. Cantor Fitzgerald was of a view on January 29, 2020 that the stock is Overweight, while William Blair gave the stock Outperform rating on January 21, 2020, issuing a price target of. Janney on their part issued Buy rating on June 27, 2018.